Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.steroids.2014.07.009 http://scihub22266oqcxt.onion/10.1016/j.steroids.2014.07.009 C4696022!4696022 !25065587     free     free     free Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\25065587 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Steroids 2015 ; 97 (ä): 2-7 Nephropedia Template TP {{tp|p=25065587 |t=2015. Targeting thapsigargin towards tumors |pdf=|usr=}}{{25065587 }} gab.com Text Targeting thapsigargin towards tumors JO: Steroids http://www.kidney.de/pget.php?&tw=1&pmid=25065587 #FOAvip The skin irritating principle from Thapsia garganica was isolated, named thapsigargin and the structure elucidated. By inhibiting the sarco/endoplasmic reticulum Ca(2+) ATPase (SERCA) thapsigargin provokes apoptosis in almost all cells. By conjugating thapsigargin to peptides, which are only substrates for either prostate specific antigen (PSA) or prostate specific membrane antigen (PSMA) prodrugs were created, which selectively affect prostate cancer cells or neovascular tissue in tumors. One of the prodrug is currently tested in clinical phase II. The prodrug under clinical trial has been named mipsagargin. Twit Text FOAVip Targeting thapsigargin towards tumors ????Steroids http://www.kidney.de/pget.php?&tw=1&pmid=25065587 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25065587 #FOAvip English Wikipedia <ref>{{Cite pmid|25065587 }}</ref> Targeting thapsigargin towards tumors #MMPMID25065587 Doan NT ; Paulsen ES ; Sehgal P ; Møller JV ; Nissen P ; Denmeade SR ; Isaacs JT ; Dionne CA ; Christensen SB Steroids 2015[May]; 97 (ä): 2-7 PMID25065587 show ga The skin irritating principle from Thapsia garganica was isolated, named thapsigargin and the structure elucidated. By inhibiting the sarco/endoplasmic reticulum Ca(2+) ATPase (SERCA) thapsigargin provokes apoptosis in almost all cells. By conjugating thapsigargin to peptides, which are only substrates for either prostate specific antigen (PSA) or prostate specific membrane antigen (PSMA) prodrugs were created, which selectively affect prostate cancer cells or neovascular tissue in tumors. One of the prodrug is currently tested in clinical phase II. The prodrug under clinical trial has been named mipsagargin. |Animals [MESH] |Antineoplastic Agents, Phytogenic/chemistry/isolation & purification/*pharmacology [MESH] |Apiaceae/*chemistry [MESH] |Apoptosis/drug effects [MESH] |Cell Proliferation/drug effects [MESH] |Enzyme Inhibitors/chemistry/isolation & purification/*pharmacology [MESH] |Humans [MESH] |Male [MESH] |Mice [MESH] |Molecular Structure [MESH] |Neovascularization, Pathologic/drug therapy/pathology [MESH] |Prodrugs/chemistry/isolation & purification/*pharmacology [MESH] |Prostatic Neoplasms/*drug therapy/pathology [MESH] |Sarcoplasmic Reticulum Calcium-Transporting ATPases/antagonists & inhibitors/metabolism [MESH] |Soft Tissue Neoplasms/*drug therapy/pathology [MESH]Targeting thapsigargin towards tumors (epmc).pdf DeepDyve Pubget Overpricing